DE69132411T2 - Retinoid-rezeptor-zusammensetzungen und verfahren - Google Patents

Retinoid-rezeptor-zusammensetzungen und verfahren

Info

Publication number
DE69132411T2
DE69132411T2 DE69132411T DE69132411T DE69132411T2 DE 69132411 T2 DE69132411 T2 DE 69132411T2 DE 69132411 T DE69132411 T DE 69132411T DE 69132411 T DE69132411 T DE 69132411T DE 69132411 T2 DE69132411 T2 DE 69132411T2
Authority
DE
Germany
Prior art keywords
receptors
novel
retinoid
compounds
transformed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69132411T
Other languages
English (en)
Other versions
DE69132411D1 (de
Inventor
John Mangelsdorf
Mark Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23898398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69132411(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Application granted granted Critical
Publication of DE69132411D1 publication Critical patent/DE69132411D1/de
Publication of DE69132411T2 publication Critical patent/DE69132411T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/75Vector systems having a special element relevant for transcription from invertebrates
DE69132411T 1990-02-09 1991-01-22 Retinoid-rezeptor-zusammensetzungen und verfahren Expired - Fee Related DE69132411T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47807190A 1990-02-09 1990-02-09
PCT/US1991/000399 WO1991012258A1 (en) 1990-02-09 1991-01-22 Retinoid receptor compositions and methods

Publications (2)

Publication Number Publication Date
DE69132411D1 DE69132411D1 (de) 2000-10-19
DE69132411T2 true DE69132411T2 (de) 2001-06-07

Family

ID=23898398

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69132411T Expired - Fee Related DE69132411T2 (de) 1990-02-09 1991-01-22 Retinoid-rezeptor-zusammensetzungen und verfahren

Country Status (9)

Country Link
US (2) US5723329A (de)
EP (2) EP0514488B1 (de)
JP (1) JPH05504479A (de)
AT (1) ATE196310T1 (de)
AU (2) AU654270B2 (de)
CA (1) CA2075182C (de)
DE (1) DE69132411T2 (de)
ES (1) ES2152920T3 (de)
WO (1) WO1991012258A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091518A (en) * 1989-11-16 1992-02-25 The Salk Institute For Biological Studies Beta retinoic acid response elements compositions and assays
DE69132411T2 (de) 1990-02-09 2001-06-07 Salk Inst For Biolog Studies L Retinoid-rezeptor-zusammensetzungen und verfahren
CA2075192A1 (en) * 1990-03-22 1991-09-23 Anthony E. Oro Insect retinoid receptor compositions and methods
DE69232537T2 (de) * 1991-09-17 2002-10-24 Salk Inst For Biolog Studies L Rezeptoren der steroid/thyroid superfamilie von rezeptoren
US7098310B1 (en) 1991-12-24 2006-08-29 Ligand Pharmaceuticals Heterodimers of retinoid X receptors (RXRS) and other steroid hormone receptors
US5756448A (en) * 1992-02-26 1998-05-26 The General Hospital Corporation Constitute activator of retinoid (CAR) receptor polypeptides
US6989242B1 (en) 1992-02-26 2006-01-24 The General Hospital Coporation Car receptors and related molecules and methods
GB9206874D0 (en) * 1992-03-30 1992-05-13 Connaught Lab Generation of improved inducible mammalian expression vectors
JPH10501986A (ja) * 1994-06-24 1998-02-24 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド レチノイン酸受容体エプシロン
US5877018A (en) * 1994-10-20 1999-03-02 Connaught Laboratories Limited Synthetic eukaryotic promoters containing two inducible elements
WO1996023070A2 (en) * 1995-01-23 1996-08-01 Ligand Pharmaceuticals Incorporated HUMAN RETINOID X RECEPTOR - GAMMA (hRXR-GAMMA)
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
CA2213340C (en) * 1995-03-03 2011-07-26 Novartis Ag Control of gene expression in plants by receptor mediated transactivation in the presence of a chemical ligand
IL123796A0 (en) 1995-10-10 1998-10-30 Novartis Ag Juvenile hormone or one of its agonists as a chemical ligand to control gene expression in plants by receptor mediated transactivation
US6893830B1 (en) 1996-09-27 2005-05-17 The Board Of Regents Of The University Of Texas System Method of screening oxysterol activation of LXRα
US6489451B1 (en) 1997-04-10 2002-12-03 Hefei-Siu-Fung Ustc Pharmaceutical Co., Ltd. Antithrombosis enzyme from the snake venom of agkistrodon acutus
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
AU9036198A (en) * 1997-08-26 1999-03-16 Ariad Gene Therapeutics, Inc. Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain
US6479653B1 (en) 1997-08-26 2002-11-12 Ariad Gene Therapeutics, Inc. Compositions and method for regulation of transcription
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US8105825B2 (en) * 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
AU2002251724B2 (en) 2000-10-24 2007-06-21 Syngenta Participations Ag Control of gene expression in plants
WO2002066615A2 (en) 2001-02-20 2002-08-29 Rheogene, Inc. Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
MXPA03007493A (es) 2001-02-20 2004-10-15 Rheogene Holdings Inc Nuevo sistema de expresion genetica inducible a base de receptor de ecdisona/receptor x retinoide de invertebrado.
EP1373470B1 (de) 2001-02-20 2013-04-24 Intrexon Corporation Neue substitutionsmutantenrezeptoren und ihre verwendung in einem induzierbaren genexpressionssystem auf basis eines nukleären rezeptors
DK1572862T3 (da) 2001-02-20 2012-11-26 Intrexon Corp Kimære, retinoide x-receptorer og deres anvendelse i et hidtil ukendt ecdysonrecepttorbaseret inducerbart genekspressionssystem
DE10244149A1 (de) * 2001-09-25 2003-04-30 Werner Keber Verfahren und Einrichtung zum Verhindern einer unzulässigen Flugannäherung von Flugzeugen an zu schützende Bodenobjeke
MXPA04002810A (es) 2001-09-26 2005-06-06 Rheogene Holdings Inc Acidos nucleicos receptores de ecdisona de saltarilla, polipeptidos, y sus usos.
CA2459807C (en) 2001-09-26 2013-09-03 Jianzhong Zhang Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
US20030170724A1 (en) * 2002-03-08 2003-09-11 Anderson David C. Methods of identifying target polypeptides
EP1489094A4 (de) * 2002-03-25 2005-11-02 Fujisawa Pharmaceutical Co Isoformen des nukleären rezeptors rxr alpha
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7935510B2 (en) * 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EA016083B1 (ru) 2005-08-09 2012-02-28 Займоджинетикс, Инк. СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
MX2008014365A (es) 2006-05-15 2008-11-27 Ares Trading Sa Metodos para tratar enfermedades autoinmunitarias utilizando una molecula de fusion del activador de transmembrana-inmunoglobulina.
NZ712167A (en) 2013-03-15 2018-05-25 Intrexon Corp Boron-containing diacylhydrazines
JP6567657B2 (ja) 2014-09-17 2019-08-28 イントレキソン コーポレーション ホウ素含有ジアシルヒドラジン化合物
US10510304B2 (en) 2016-08-10 2019-12-17 Manufacturing Resources International, Inc. Dynamic dimming LED backlight for LCD array
KR20190142775A (ko) 2017-04-19 2019-12-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2603280B1 (fr) * 1986-08-29 1988-10-28 Cird Nouveau compose marque au tritium, sa preparation et son application notamment dans la determination de l'affinite des retinoides pour leur recepteur cellulaire
US5171671A (en) * 1987-12-02 1992-12-15 The Salk Institute For Biological Studies Retinoic acid receptor composition
US5274077A (en) * 1987-12-02 1993-12-28 The Salk Institute For Biological Studies Retinoic acid receptor composition
US5571692A (en) * 1987-12-02 1996-11-05 The Salk Institute For Biological Studies Retinoic acid receptor α, vectors and cells comprising the same DNA encoding
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5260432A (en) * 1989-06-22 1993-11-09 Sloan-Kettering Institute For Cancer Research Human gamma retinoic acid receptor DNA
US5403925A (en) * 1989-12-13 1995-04-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleic acids encoding mammalian H-2RIIBP or RXR.sub.β and uses thereof
DE69132411T2 (de) 1990-02-09 2001-06-07 Salk Inst For Biolog Studies L Retinoid-rezeptor-zusammensetzungen und verfahren
DE69232537T2 (de) * 1991-09-17 2002-10-24 Salk Inst For Biolog Studies L Rezeptoren der steroid/thyroid superfamilie von rezeptoren
JPH06510206A (ja) * 1992-01-24 1994-11-17 アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル 新規ヘテロダイマー核レセプタータンパク質、それをコードする遺伝子、およびその使用

Also Published As

Publication number Publication date
AU1155395A (en) 1995-05-25
EP0514488A1 (de) 1992-11-25
US7501487B1 (en) 2009-03-10
WO1991012258A1 (en) 1991-08-22
EP0999271A2 (de) 2000-05-10
EP0514488A4 (en) 1993-02-17
AU680575B2 (en) 1997-07-31
ATE196310T1 (de) 2000-09-15
JPH05504479A (ja) 1993-07-15
CA2075182A1 (en) 1991-08-10
US5723329A (en) 1998-03-03
CA2075182C (en) 2003-03-25
ES2152920T3 (es) 2001-02-16
DE69132411D1 (de) 2000-10-19
EP0514488B1 (de) 2000-09-13
EP0999271A3 (de) 2003-04-02
AU7338391A (en) 1991-09-03
AU654270B2 (en) 1994-11-03

Similar Documents

Publication Publication Date Title
DE69132411T2 (de) Retinoid-rezeptor-zusammensetzungen und verfahren
NL300043I1 (nl) Middelen voor het moduleren van processen die worden verzorgd door retonoïde receptoren en verbindingen die daarvoor nuttig zijn.
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
DK1012274T3 (da) Dödsdomæneholdig receptor-4 (DR4: dödsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
NO982794D0 (no) Diagnostisering og behandling av AUR-1 og/eller AUR-2 relaterte lidelser
DE69317883T2 (de) Neue Sieben-Transmembran-Rezeptor V28
NO2010021I1 (no) Denosumab
ATE266671T1 (de) Nukleinsäuresynthese unter verwendung von mittels licht abspaltbaren schutzgruppen
ATE263836T1 (de) Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
EP1517144A3 (de) Verfahren zur Identifizierung eines Antikörpers, der einen humanen Vanilloid Rezeptor bindet und dessen Aktivität moduliert
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
DK1007666T3 (da) Neurturinreceptor
DE69634134D1 (de) Klonierung von pheromon rezeptoren aus vertebraten und deren verwendungen
DE69231689T2 (de) Zusammensetzung von antwortelementen und ihre verwendung als proben
ATE273514T1 (de) Methode zum bestimmen der aktivierung von zytokinrezeptoren mit hilfe eines antikörpers
ATE449166T1 (de) Chimere zielmoleküle mit regulierbarer aktivität
DE60129719D1 (de) Screening-verfahren zum identifizieren von g-proteinen und anderen verbindungen,die die phosphodiesterase (pde)-aktivität beeinflussen
ATE195151T1 (de) Verfahren zur bewertung von substanzen zum steigen bzw. zur modifizierung der apc-aktivität
RETH et al. Structure and Signaling Function of B Cell Antigen Receptors of Different Classes

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee